338 related articles for article (PubMed ID: 25808652)
1. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
Khan K; Cunningham D; Chau I
Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
[TBL] [Abstract][Full Text] [Related]
2. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
3. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
Kato S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Clarke JM; Hurwitz HI; Rangwala F
Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
7. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
8. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
9. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
McIntyre K
Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
[TBL] [Abstract][Full Text] [Related]
10. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
Gill S; Dowden S; Colwell B; Collins LL; Berry S
Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
[TBL] [Abstract][Full Text] [Related]
11. [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
[TBL] [Abstract][Full Text] [Related]
12. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
13. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
18. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
19. [Targeted therapies for metastatic colorectal cancer].
Kito Y; Yamazaki K
Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
[TBL] [Abstract][Full Text] [Related]
20. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
